Jump to ContentJump to Main Navigation

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Editorial Board Member: Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Schlattmann, Peter / Tate, Jillian R. / Tsongalis, Gregory J.

13 Issues per year


IMPACT FACTOR 2013: 2.955
Rank 5 out of 29 in category Medical Laboratory Technology in the 2013 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR): 0.860
Source Normalized Impact per Paper (SNIP): 1.046

VolumeIssuePage

Issues

Pandemic influenza A (H1N1) 2009: the experience of the first six months

Jean Maritz1 / Leana Maree1 / Wolfgang Preiser1

1Division of Medical Virology, Department of Pathology, National Health Laboratory Service and University of Stellenbosch, Cape Town, South Africa

Corresponding authors: Jean Maritz, MBChB MSc and Leana Maree, MBChB, Division of Medical Virology, Department of Pathology, National Health Laboratory Service and University of Stellenbosch, Cape Town 7505, South Africa Phone: +27 21 938 9347, Fax: +27 21 938 9361, ;

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 48, Issue 1, Pages 11–21, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: 10.1515/CCLM.2010.023, December 2009

Publication History

Received:
2009-11-21
Accepted:
2009-11-23
Published Online:
2009-12-22

Abstract

After a break of 41 years, 2009 saw the first influenza pandemic of the 21st century caused by a triple-reassortant influenza A (H1N1) virus. The current estimated case fatality rate is lower than that of previous influenza pandemics, but this may change as the pandemic evolves. Illness frequently occurs in previously healthy, young adults with a wide range of clinical presentations. The majority of circulating pandemic viruses remain susceptible to neuraminidase inhibitors, although all strains are intrinsically resistant to the adamantanes. Monovalent vaccines against the pandemic strain are available in both live attenuated and inactivated forms. This review aims to summarise important virological, epidemiological and clinical aspects of the pandemic influenza A (H1N1) virus for physicians and other clinical personnel.

Clin Chem Lab Med 2010;48:11–21.

Keywords: H1N1; influenza A virus; pandemic; review; swine flu

Comments (0)

Please log in or register to comment.